Effects of neuronal nicotinic acetylcholine receptor allosteric modulators in animal behavior studies.

Chukchi Campus, Department of Bio-science, College of Rural and Community Development, University of Alaska Fairbanks, P.O. Box-297, Kotzebue, AK. 99752-0297. USA. Electronic address: .
Biochemical pharmacology (Impact Factor: 4.65). 05/2013; DOI: 10.1016/j.bcp.2013.05.018
Source: PubMed

ABSTRACT Nicotinic acetylcholine receptors (nAChRs) are ligand-gated cation-conducting transmembrane channels from the cys-loop receptor superfamily. The neuronal subtypes of these receptors (e.g. the α7 and α4β2 subtypes) are involved in neurobehavioral processes such as anxiety, the central processing of pain, food intake, nicotine seeking behavior, and a number of cognitive functions like learning and memory. Neuronal nAChR dysfunction is involved in the pathophysiology of many neurological disorders, and behavioral studies in animals are useful models to assess the effects of compounds that act on these receptors. Allosteric modulators are ligands that bind to the receptors at sites other than the orthosteric site where acetylcholine, the endogenous agonist for the nAChRs, binds. While conventional ligands for the neuronal nAChRs have been studied for their behavioral effects in animals, allosteric modulators for these receptors have only recently gained attention, and research on their behavioral effects is growing rapidly. Here we will discuss the behavioral effects of allosteric modulators of the neuronal nAChRs.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Activation of nicotinic acetylcholine receptors (nAChRs) is associated with the binding of agonists such as acetylcholine to an extracellular site that is located at the interface between two adjacent receptor subunits. More recently, there has been considerable interest in compounds, such as positive and negative allosteric modulators (PAMs and NAMs), that are able to modulate nAChR function by binding to distinct allosteric sites. Here we examined a series of compounds, differing only in methyl-substitution of a single aromatic ring. This series of compounds includes a previously described α7-selective allosteric agonist, 4MP-TQS, together with all other possible combinations of methyl-substitution at a phenyl ring (18 additional compounds). Studies conducted with this series of compounds have revealed five distinct pharmacological effects on α7 nAChRs. These five effects can be summarised as: 1) non-desensitising activation (allosteric agonists), 2) potentiation associated with minimal effects on receptor desensitisation (type I PAMs), 3) potentiation associated with reduced desensitisation (type II PAMs), 4) non-competitive antagonism (NAMs) and 5) compounds that have no effect on orthosteric agonist responses but block allosteric modulation (silent allosteric modulators; SAMs). Several lines of experimental evidence are consistent with all of these compounds acting at a common, mutually exclusive, transmembrane allosteric site. Notably, all of these chemically similar compounds that have been classified as non-desensitising allosteric agonists or as non-desensitising (type II) PAMs are cis-cis diastereoisomers, whereas all of the NAMs, SAMs and type I PAMs are cis-trans diastereoisomers. Our data illustrate the remarkable pharmacological diversity of allosteric modulators acting on nAChRs. Copyright © 2014, The American Society for Biochemistry and Molecular Biology.
    Journal of Biological Chemistry 12/2014; DOI:10.1074/jbc.M114.619221 · 4.60 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The neurotransmitter acetylcholine (ACh) can regulate neuronal excitability by acting on the cys-loop cation-conducting ligand-gated nicotinic ACh receptor (nAChR) channels. These receptors are widely distributed throughout the central nervous system (CNS), being expressed on neurons and non-neuronal cells, where they participate in a variety of physiological responses such as anxiety, the central processing of pain, food intake, nicotine seeking behavior, and cognitive functions. In the mammalian brain, nine different subunits have been found thus far, which assemble into pentameric complexes with much subunit diversity; however, the α7 and α4β2 subtypes predominate in the CNS. Neuronal nAChR dysfunction is involved in the pathophysiology of many neurological disorders. Here we will briefly discuss the functional makeup and expression of the nAChRs in mammalian brain, and their role as targets in neurodegenerative diseases (in particular Alzheimer's disease, AD), neurodevelopmental disorders (in particular autism and schizophrenia), and neuropathic pain. Published by Elsevier Ltd.
    Trends in Pharmacological Sciences 01/2015; DOI:10.1016/ · 9.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Most individuals with schizophrenia suffer some cognitive dysfunction: such deficits are predictive of longer-term functioning; and current dopamine-blocking antipsychotics have made little impact on this domain. There is a pressing need to develop novel pharmacological agents to tackle this insidious but most disabling of problems. The acetylcholinergic system is involved in cognitive and attentional processing, and its metabotropic and nicotinic receptors are widespread throughout the brain. Deficits in acetylcholinergic functioning occur in schizophrenia, and high rates of tobacco smoking have been posited to represent a form of self-medication. The nicotinic acetylcholine receptor (nAChR) has emerged as a putative target to improve cognitive deficits in schizophrenia, and this study systematically reviewed the emerging data. Nineteen studies were identified, covering three compound classes: agonists at the α7 and α 4β2 nAChRs, and positive allosteric modulators. Overall data are underwhelming: some studies showed significant improvements in cognition but as many studies had negative findings. It remains unclear if this represents drug limitations or nascent study methodology problems. The literature is particularly hindered by variability in inclusion of smokers, generally small sample sizes, and a lack of consensus on cognitive test batteries. Future work should evaluate longer-term outcomes, and, particularly, the effects of concomitant cognitive training. © The Author(s) 2015.
    Journal of Psychopharmacology 01/2015; 29(2). DOI:10.1177/0269881114564096 · 2.81 Impact Factor


Available from
Feb 20, 2015